Stock CERE CEREVEL THERAPEUTICS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Cerevel Therapeutics Holdings, Inc.

Equities

CERE

US15678U1280

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
42.47 USD +0.95% Intraday chart for Cerevel Therapeutics Holdings, Inc. +0.62% +0.17%
Apr. 18 Sector Update: Health Care Stocks Mixed Pre-Bell Thursday MT
Apr. 18 Cerevel Therapeutics' Potential Parkinson's Treatment Meets Primary Endpoint in Phase 3 Study MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease
AQ
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
AQ
CERE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Cerevel Therapeutics Holdings, Inc. Is Fair to Shareholders
BU
CEREVEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cerevel Therapeutics - CERE
BU
AbbVie to buy neuroscience specialist Cerevel Therapeutics for $8.7bn
AQ
JetBlue Airways, Semtech rise; Duckhorn, Chewy fall, Thursday, 12/7/2023
AQ
Shareholder Alert: Ademi LLP investigates whether Cerevel Therapeutics has obtained a Fair Price in its transaction with AbbVie
PR
CERE MERGER ANNOUNCEMENT: Julie & Holleman LLP Announces Investigation Into Potential Claims Regarding AbbVie's Proposed Acquisition of Cerevel Therapeutics
PR
CERE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Cerevel Therapeutics Holdings, Inc. Is Fair to Shareholders
BU
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
PR
Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease
AQ
Cerevel Therapeutics to Present at Upcoming Investor Conferences
AQ
Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
AQ
Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023
AQ
Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock
AQ
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock
AQ
Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cerevel Therapeutics Holdings, Inc. - CERE
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cerevel Therapeutics Holdings, Inc. - CERE
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cerevel Therapeutics Holdings, Inc. - CERE
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CERE Stock
  4. News Cerevel Therapeutics Holdings, Inc.
  5. Press Releases